Press coverage about Diplomat Pharmacy (NYSE:DPLO) has trended somewhat positive on Friday, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Diplomat Pharmacy earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.6100087734668 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Diplomat Pharmacy, Inc. (DPLO) Position Up in Latest Report from Dynamic Technology Lab Private Ltd - First News 24 (firstnewspaper24.com)
- Diplomat Pharmacy, Inc. (NYSE:DPLO) Closed 5.2% Above Its 50 Day Average - Modern Readers (modernreaders.com)
- Sysco Corporation (SYY) and Diplomat Pharmacy (DPLO) Critical Survey (americanbankingnews.com)
- Technical Focus on Shares of Diplomat Pharmacy Inc (DPLO) - Financial News Review (finnewsreview.com)
- Diplomat Pharmacy (DPLO) Says It’s Dispensing MAVYRET to Treat Chronic Hepatitis C - StreetInsider.com (streetinsider.com)
Diplomat Pharmacy (DPLO) traded up 1.05% during trading on Friday, reaching $16.43. The company’s stock had a trading volume of 485,312 shares. The stock has a 50-day moving average price of $15.49 and a 200 day moving average price of $15.85. The company has a market cap of $1.12 billion, a PE ratio of 89.78 and a beta of 0.66. Diplomat Pharmacy has a 52-week low of $12.25 and a 52-week high of $34.55.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Monday, August 7th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.10. The company had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.14 billion. Diplomat Pharmacy had a return on equity of 7.97% and a net margin of 0.27%. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.23 EPS. On average, analysts expect that Diplomat Pharmacy will post $0.75 EPS for the current year.
Several analysts recently weighed in on DPLO shares. Mizuho upped their price objective on Diplomat Pharmacy from $17.00 to $19.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 16th. Zacks Investment Research downgraded Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. BidaskClub downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. Bank of America Corporation upped their price objective on Diplomat Pharmacy from $17.00 to $18.50 and gave the stock a “neutral” rating in a research report on Thursday, May 25th. Finally, Needham & Company LLC started coverage on Diplomat Pharmacy in a research report on Friday, July 21st. They set a “buy” rating and a $19.75 price objective for the company. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $17.89.
ILLEGAL ACTIVITY NOTICE: This article was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://stocknewstimes.com/2017/08/18/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-diplomat-pharmacy-dplo-share-price.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
